DME/Retina Edition: Top Headlines for Week of July 8, 2024

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:

FDA approves Vabysmo prefilled syringe for retinal diseases

VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates

FDA approves Eylea biosimilar FYB203/Ahzantive

VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

ANI Pharmaceuticals to acquire Alimera Sciences

References:

Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

Press Release

Press Release

Press Release

Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.